Welcome to our dedicated page for Petmed Express SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetMed Express, Inc. (PETS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and related documents filed with the U.S. Securities and Exchange Commission. As a Florida-incorporated public company listed on Nasdaq, PetMed Express uses these filings to report its financial results, governance decisions, internal control assessments, and material corporate events.
PetMed Express’s recent filings highlight several key themes. The company filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, which incorporates restated financial information following an Audit Committee investigation into revenue recognition practices, vendor promotional reimbursements, and internal controls. In related 8-K filings, the company disclosed that certain prior financial statements should no longer be relied upon due to income statement classification errors and that it expects to report material weaknesses in internal control over financial reporting.
Multiple 8-K and Form 12b-25 (NT 10-Q) filings detail delays in filing the company’s Annual Report and Quarterly Reports, along with Nasdaq notices of non-compliance with Listing Rule 5250(c)(1). These documents describe the company’s plans to complete outstanding filings and seek to regain compliance within the timeframes allowed by Nasdaq. Other 8-K filings cover a non-cash impairment charge related to an indefinite-lived intangible asset associated with the PetCareRx trade name, as well as governance and compensation matters such as leadership changes, interim executive employment terms, and change-of-control and severance arrangements.
Investors can also review filings related to PetMed Express’s shareholder rights plan, including an amendment extending the expiration date of the rights, and disclosures about unsolicited, non-binding acquisition proposals referenced in Schedule 13D amendments and company press releases. Stock Titan’s platform surfaces these filings in real time from EDGAR and pairs them with AI-powered summaries that explain the significance of each document. Users can quickly understand the implications of PetMed Express’s 10-K and 10-Q reports, 8-K event disclosures, and any Form 4 insider transaction reports, helping them interpret complex regulatory information more efficiently.
PetMed Express, Inc. received a Schedule 13D from Diveroli Investment Group LLC and Kingbird Ventures LLC disclosing a stake in its common stock. The reporting persons beneficially own 391,757 shares, representing 1.83% of PetMed’s outstanding common stock, based on 21,400,495 shares outstanding as of January 30, 2026.
The shares are held in the name of Kingbird Ventures LLC, with Diveroli Investment Group LLC acting as its authorized representative. The investors describe their principal business as investing in public and private companies and state they may buy more or sell shares over time depending on market and company factors, but do not currently have specific plans for corporate changes at PetMed.
PetMed Express reported a sharp downturn for the quarter ended December 31, 2025. Net sales fell to $40.7 million from $52.0 million, a 21.7% decline, driven mainly by weaker prescription medication demand and heavier promotions. The company posted a quarterly net loss of $10.6 million versus a $0.7 million loss a year earlier.
For the nine months, sales dropped to $136.2 million from $176.2 million, and results swung from $5.4 million of income to a $53.2 million loss, including a $26.7 million goodwill impairment, a $0.6 million trade name impairment, and a $2.1 million inventory write-down. Cash and cash equivalents decreased to $26.9 million from $54.7 million, while shareholders’ equity fell to $32.8 million. The company also restated prior-year figures to correct vendor rebate accounting and disclosed unsolicited, non-binding cash acquisition proposals at $4.00–$4.25 per share, which its board is reviewing.
PetMed Express director Gian Fulgoni reported an automatic forfeiture of 26,057 shares of common stock on January 21, 2026. The Form 4 shows this as a disposition at a price of $0.00 per share, reflecting that the shares were forfeited rather than sold for cash.
According to the footnote, the forfeiture was required under the applicable award agreement for restricted shares that had been granted on October 30, 2025, and occurred due to the termination of his director service as of January 21, 2026. After this change, Fulgoni directly beneficially owns 132,299 shares of PetMed Express common stock.
PetMed Express reported the results of its Annual Meeting of Shareholders held on January 21, 2026. As of the December 5, 2025 record date, 21,372,021 voting shares were outstanding, and 15,506,165 shares were represented in person or by proxy, providing a quorum.
Shareholders elected all five board nominees to serve until the next annual meeting. For example, votes for director Peter Batushansky were 7,250,849 for, 3,099,547 against, with 49,472 abstentions and 5,106,297 broker non-votes, and similar support levels were recorded for the other nominees.
On an advisory basis, shareholders approved the compensation of the named executive officers, with 8,530,380 votes for, 1,787,060 against and 82,428 abstentions, plus 5,106,297 broker non-votes. They also ratified the appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year 2026, with 14,979,224 votes for, 448,313 against and 78,628 abstentions.
PetMed Express, Inc. (PETS) reported that it entered into an amendment to its shareholder rights agreement, extending the final expiration date of the rights until the close of business on December 2, 2026. This keeps its preferred stock purchase rights plan in place for an additional year.
The Board also approved an increase in the annual base salary of Interim Principal Financial Officer and Chief Accounting Officer Douglas Krulik from $300,000 to $330,000, effective as of August 30, 2025. In addition, the Company entered into a Change of Control and General Severance Agreement with Mr. Krulik, providing six months of base-salary severance if he is terminated without cause, and, if such termination or a resignation for good reason occurs within 12 months after a change of control, the same severance plus immediate vesting of his restricted equity awards.
PetMed Express reported receiving a Nasdaq notice on November 12, 2025 for failing to timely file its Quarterly Reports on Form 10‑Q for the periods ended June 30, 2025 (Q1) and September 30, 2025 (Q2), in addition to a prior delinquent Form 10‑K for the year ended March 31, 2025. The notice requires an updated compliance plan by November 28, 2025, and states any staff exception, if granted, will be limited to a maximum of 180 days from the initial delinquency, or December 29, 2025.
The company said the notice has no immediate effect on its Nasdaq listing and it intends to complete and file the Q1 10‑Q and Q2 10‑Q as promptly as possible. Separately, PetMed furnished a press release announcing preliminary, unaudited estimated revenues for the three‑ and nine‑month periods ended September 30, 2025; that information was furnished, not filed, under Item 2.02.
PetMed Express (PETS) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the quarter ended September 30, 2025, as it first needs to complete the delayed June 30, 2025 Form 10-Q following a now-completed Audit Committee investigation.
For the September quarter, net sales are estimated at $43.4–$44.5 million, compared with $58.0 million in the prior-year period. For the six months ended September 30, 2025, net sales are expected at $94.5–$95.6 million, versus $124.3 million a year earlier. The company is analyzing the timing and amount of an anticipated goodwill impairment and cannot currently estimate operating or net income for these periods.
PetMed Express (PETS) reported that its CAO and Interim CFO acquired 20,000 shares of restricted stock on October 30, 2025 at $0, as disclosed on a Form 4.
The award vests as to 50% of the granted shares on October 30, 2026 and 50% on October 30, 2027, subject to continued employment through each vesting date. Following this grant, the officer beneficially owns 70,000 shares.
PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4. Following the award, the director beneficially owns 34,866 shares, held directly. The grant was made under the company’s 2024 Omnibus Incentive Plan and is scheduled to vest in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, each vesting subject to continued service on the Board of Directors.
PetMed Express (PETS) reported a director equity grant. The reporting person acquired 33,846 shares of common stock as a restricted stock award at $0 on October 30, 2025, issued under the company’s 2024 Omnibus Incentive Plan. The award vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors. After this transaction, the reporting person beneficially owned 42,719 shares, held directly.